IP Library Granted Patent US 9,956,247
Granted Patent B2
US 9,956,247 · App. 13/939,794 · Granted May 1, 2018

Method of treating lysosomal storage diseases

Inventor: Edward J. Rebar (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
A61K35/28A61K38/46A61K38/465A61K48/005C12N9/22C12N15/907A61K48/00C07K2319/81
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,956,247
App. No.
13/939,794
Granted
May 1, 2018
Kind
B2
Abstract

Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for the provision of proteins lacking or deficient in subjects with a lysosomal storage disease and treatment and/or prevention of lysosomal storage diseases.

Claims (6)

1. A method for expressing and secreting exogenous glucocerebrosidase (GBA), α galactosidase (GLA), iduronate-2-sulfatase (IDS) or alpha-L iduronidase (IUDA) protein in a liver cell of a human or a mouse in need thereof, the method comprising:

(a) intravenously administering one or more AAV vectors encoding a pair of zinc finger nucleases that cleaves in intron 1 or 12 of an endogenous albumin gene into said human or mouse containing the liver cell and disrupts expression of the albumin gene; and

(b) intravenously administering an AAV vector comprising a donor sequence comprising a transgene encoding: (i) an exogenous GBA protein; (ii) an exogenous GLA protein; (iii) an exogenous IDS protein; or (iv) an exogenous IDUA protein, into the human or mouse liver cell of said human or mouse, wherein the transgene encoding the protein is flanked by regions of homology to intron 1 or 12 of the cleaved endogenous albumin gene, such that the transgene is integrated by homology directed repair into intron 1 or 12 of the cleaved endogenous albumin gene, and the liver cell expresses and secretes the exogenous GBA, GLA, IDS, or IDUA protein.

2. The method of claim 1 , wherein the transgene encodes iduronate-2-sulfatase or alpha-L iduronidase.

3. The method of claim 1 , wherein expression of the transgene is driven by the endogenous albumin promoter.

4. The method of claim 1 , wherein the transgene encodes a fusion protein comprising amino acids encoded by the transgene and by the endogenous locus into which the transgene is integrated.

Assignments (2)
CHANGE OF NAME Recorded Oct 13, 2017
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 044264/0292 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2013
From: REBAR, EDWARD J.
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 031823/0211 →
Continuity (3)
Provisional Application 61670463 · Jul 11, 2012
Provisional Application 61704072 · Sep 21, 2012
Related Publication 20140112896A1 · Apr 24, 2014